title: Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.
abstract: BACKGROUND
  Several classes of medications improve survival in patients with coronary artery disease. Whether these medications, as used in the real world, have additive efficacy remains speculative.
  
  
  OBJECTIVE
  To assess whether patients discharged on combined secondary prevention medications after acute myocardial infarction (AMI) have improved 1-year survival, compared with the action of any single class of medications.
  
  
  METHODS
  Nationwide registry of consecutive patients admitted to intensive care units for AMI in November 2000 in France. Multivariate Cox regression analysis, including a propensity score for the prescription of combined therapy, was used.
  
  
  RESULTS
  Of the 2119 patients discharged alive, 1095 (52%) were prescribed a combination of antiplatelet agents, beta-blockers, and statins (triple therapy), of whom 567 (27%) also received angiotensin-converting enzyme inhibitors (quadruple therapy) and 528 (25%) did not. One-year survival was 97% in patients receiving triple combination therapy versus 88% in those who received either none, 1, or 2 of these medications (P < .0001). After multivariate adjustment including the propensity score, the hazard ratio for 1-year mortality in patients with triple combination therapy was 0.52 (95% CI 0.33-0.81). In patients with ejection fraction < or = 35%, beta-blockers and angiotensin-converting enzyme inhibitors were independent predictors of survival, and combination therapy had no additional prognostic value.
  
  
  CONCLUSIONS
  Compared with the prescription of any single class of secondary prevention medications, combination therapy offers additional protection in patients with AMI.
authors.affiliation: Hôpital Européen Georges Pompidou, Paris, France. nicolas.danchin@egp.ap-hop-paris.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Danchin
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Cambou
authors.forename: Guy
authors.initials: G
authors.lastname: Hanania
authors.forename: Zena
authors.initials: Z
authors.lastname: Kadri
authors.forename: Nathalie
authors.initials: N
authors.lastname: Genès
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Lablanche
authors.forename: Didier
authors.initials: D
authors.lastname: Blanchard
authors.forename: Laurent
authors.initials: L
authors.lastname: Vaur
authors.forename: Pierre
authors.initials: P
authors.lastname: Clerson
authors.forename: Pascal
authors.initials: P
authors.lastname: Guéret
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D012042:Registries; D012044:Regression Analysis
chemical_list: D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors